5ALPHA-REDUCTASE INHIBITORS FOR REDUCTION OF PROSTATE EPITHELIAL CELL GROWTH

5 种减少前列腺上皮细胞生长的α-还原酶抑制剂

• 批准号: 8167834
• 负责人: BRIAN L LINDSHIELD
• 金额: $ 2.37万
• 依托单位: KANSAS STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167834
• 关键词: American; Androgens; Automobile Driving; Benign Prostatic Hypertrophy; Botanicals; Cell Proliferation; Computer Retrieval of Information on Scientific Projects Database; Development; Diagnosis; Dutasteride; Effectiveness; Enzymes; Epithelial Cells; Finasteride; Funding; Grant; Growth; Institution; Malignant Neoplasms; Malignant neoplasm of prostate; Nutrient; Oxidoreductase; Prostate; Public Health; Reporting; Research; Research Personnel; Resources; Sabal serrulata; Sales; Saw palmetto extract; Source; Stanolone; Testosterone; Therapeutic; United States National Institutes of Health; cell growth; combat; implantation; inhibitor/antagonist; male; men; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Prostate cancer is the most commonly diagnosed male cancer. Thus, preventative and/or therapeutic strategies to combat this cancer could have a profound impact on public health. The 5¿-reductase inhibitors finasteride (Proscar¿) and dutasteride (Avodart¿) are commonly used to treat benign prostatic hyperplasia (BPH) but may also potentially decrease the development and/or progression of prostate cancer. 5¿-reductase enzymes convert testosterone to the more potent androgen dihydrotestosterone, which is important for driving the growth of most prostate cancers. Specific Aim 1 will examine the effectiveness of finasteride and dutasteride when begun before or after tumor implantation. Saw palmetto extracts have also been used to treat BPH and are reported to decrease 5¿-reductase enzymes, but there has been a lot of inconsistency their reported effectiveness. Despite the saw palmetto's questionable effectiveness, it is commonly used by Americans, ranking in the top 5 of botanical sales and is commonly used by men with prostate cancer. We believe that the variable results between studies may be due to differences in the extracts nutrient profiles, which have been reported to vary widely. Specific Aim 2 we will collect commonly used commercial saw palmetto extracts and characterize their nutrient profiles. We will then determine whether an extract's nutrient profile correspond to its ability to inhibit 5¿-reductase and cell proliferation of prostate cancer epithelial cells.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 前列腺癌是最常诊断的男性癌症。因此，对抗这种癌症的预防和/或治疗策略可能对公众健康产生深远的影响。 5-还原酶抑制剂非那雄胺 (Proscar) 和度他雄胺 (Avodart) 通常用于治疗良性前列腺增生 (BPH)，但也可能潜在地减少前列腺癌的发生和/或进展。 5¿-还原酶将睾酮转化为更有效的雄激素二氢睾酮，这对于驱动 大多数前列腺癌的生长。具体目标 1 将检查非那雄胺和度他雄胺在肿瘤植入之前或之后开始的有效性。锯棕榈提取物也已用于治疗良性前列腺增生，据报道可降低 5'-还原酶，但其报道的功效存在很多不一致之处。尽管锯棕榈的功效值得怀疑，但它却被美国人广泛使用，在植物药销量中名列前五，并且常被患有前列腺癌的男性使用。我们认为，研究之间的不同结果可能是由于提取物营养成分的差异所致，据报道，提取物营养成分差异很大。具体目标 2 我们将收集常用的商业锯棕榈提取物并表征其营养成分。然后我们将确定提取物的营养成分是否与其抑制 5'-还原酶和前列腺癌上皮细胞的细胞增殖的能力相对应。